← Back to Search

mTOR Inhibitor

Everolimus for Tracheal Stenosis

Baltimore, MD
Phase < 1
Waitlist Available
Led By Alexander Hillel, MD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Current diagnosis of laryngotracheal stenosis
Participants must have also had a prior suspension microlaryngoscopy with endoscopic excision of scar and balloon dilation procedure prior to study entry
Must not have
HTLV 1 or 2 positive
Use of corticosteroids (glucocorticoids) within 7 days of everolimus administration (except physiologic dose equivalent)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing the drug everolimus to see if it can reduce the number of surgeries needed for patients with idiopathic Subglottic Stenosis (iSGS), a condition where scar tissue blocks the airway. Everolimus helps by calming the immune system and reducing scar tissue formation. If successful, this could lead to everolimus becoming an approved treatment for iSGS.

See full description
Who is the study for?
Adults aged 18-80 with laryngotracheal stenosis, who've had a specific throat surgery, can join this trial. They must understand the study and agree to participate. Key health markers like liver function and kidney function need to be within certain limits. Pregnant women, those with severe lung disease unrelated to their stenosis, recent participants in other drug trials, people with active autoimmune diseases or recent cancers (except some skin cancers), organ transplant recipients on immunosuppressants, and individuals not fully vaccinated against COVID-19 are excluded.Check my eligibility
What is being tested?
The AERO trial is testing an oral tablet called everolimus as a potential treatment for patients with idiopathic Subglottic Stenosis—a condition causing scar-induced airway obstruction—to reduce the number of required surgeries. This proof-of-concept study could pave the way for larger trials if successful.See study design
What are the potential side effects?
Everolimus may cause side effects such as increased risk of infections due to its immune-suppressing properties; it might also interact negatively with certain other drugs leading to more complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with narrowing of the windpipe.
 show original
Select...
I've had a throat surgery involving scar removal and stretching.
 show original
Select...
I am fully active or can carry out light work.
 show original
Select...
I am between 18 and 80 years old.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have tested positive for HTLV 1 or 2.
 show original
Select...
I haven't taken corticosteroids in the last 7 days, except for low doses.
 show original
Select...
I have been diagnosed with moderate to severe heart failure in the last 6 months.
 show original
Select...
I have not taken antibiotics or antiviral drugs in the last 7 days.
 show original
Select...
I cannot take everolimus due to an allergy or bad reaction.
 show original
Select...
I am currently taking medication that affects liver enzyme levels.
 show original
Select...
I haven't taken immunosuppressive drugs in the last 21 days and don't expect to need them during the study.
 show original
Select...
I have a severe lung condition not related to airway narrowing, with very low lung function scores.
 show original
Select...
I have had an organ transplant and am on immunosuppressants.
 show original
Select...
I am not pregnant, breastfeeding, nor planning to become pregnant.
 show original
Select...
I am currently taking medication that affects my liver's ability to process drugs.
 show original
Select...
I haven't had any cancer except for skin cancer in the last 5 years.
 show original
Select...
I am currently taking medication to suppress my immune system.
 show original
Select...
I am taking medication that could cause swelling under the skin.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Peak Expiratory flow in patients with Laryngotracheal Stenosis
Secondary study objectives
Change in 12-Item Short Form (SF-12) Survey Global Quality of Life Score
Change in Clinical COPD Questionnaire Quality of Life Score
Change in Eating Assessment Tool (EAT-10) Swallow Quality of Life Score
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Adjuvant Everolimus After Surgical DilationExperimental Treatment1 Intervention
Individuals will take low dose everolimus for 6 weeks after dilation.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Subglottic Tracheal Stenosis (SGTS) treatments focus on reducing scar tissue formation to keep the airway open. Everolimus, an immunosuppressant, is being studied for its ability to inhibit pathways that cause scar formation, potentially decreasing the need for repeated surgeries. This is important for SGTS patients as it can improve their quality of life by minimizing airway obstruction and reducing the frequency of invasive procedures.

Find a Location

Closest Location:Johns Hopkins Outpatient Center· Baltimore, MD

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,339 Previous Clinical Trials
14,881,611 Total Patients Enrolled
Alexander Hillel, MDPrincipal InvestigatorJohns Hopkins School of Medicine
2 Previous Clinical Trials
103 Total Patients Enrolled

Media Library

Everolimus (mTOR Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05153668 — Phase < 1
Subglottic Tracheal Stenosis Research Study Groups: Adjuvant Everolimus After Surgical Dilation
Subglottic Tracheal Stenosis Clinical Trial 2023: Everolimus Highlights & Side Effects. Trial Name: NCT05153668 — Phase < 1
Everolimus (mTOR Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05153668 — Phase < 1
Subglottic Tracheal Stenosis Patient Testimony for trial: Trial Name: NCT05153668 — Phase < 1
~1 spots leftby Mar 2025